Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 18,734 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Renal Impairment
Interventions: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr); Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: allo-APZ2-EB; Biological
Lead sponsor: RHEACELL GmbH & Co. KG; Industry
Eligibility: 0 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Renal Impairment
Interventions: HM15912; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Lattice Extreme Ablative Dose Radiation Therapy, Standard IMRT; Radiation
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
Interventions: BFB-101 (AAV9-CBh-AP4B1); Biological
Lead sponsor: BlackfinBio Ltd; Industry
Eligibility: 12 Months to 60 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contrast Induced Nephropathy
Interventions: N-acetylcysteine; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, epoetin alfa; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Hemopurifier, Pembrolizumab 200mg IV; Device · Drug
Lead sponsor: Aethlon Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Bortezomib, Carboplatin, Docetaxel; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: COVID-19
Interventions: ALG-097558; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Solid Tumor
Interventions: Selinexor, Acetaminophen; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Tampa, Florida • Detroit, Michigan • New York, New York + 1 more

Conditions: Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer, Neoplasm
Interventions: SAR443216 IV, SAR443216 SC; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prosthesis Related Infections
Interventions: [124I]FIAU; Radiation
Lead sponsor: BioMed Valley Discoveries, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Little Rock, Arkansas • Baltimore, Maryland • Lake Success, New York

Conditions: Carcinoma, Hepatocellular
Interventions: Stereotactic Body Radiation; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy Volunteers
Interventions: tanezumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control; Other
Lead sponsor: Andrew Slivka; Other
Eligibility: 40 Years to 70 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CC-97540, Lymphodepletion Chemotherapy; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pemphigus Vulgaris
Interventions: DSG3-CAART, CABA-201; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 13
States / cities: Redwood City, California • Sacramento, California • New Haven, Connecticut + 9 more

Conditions: Lymphoma, Precancerous/Nonmalignant Condition
Interventions: PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid, Zidovudine; Biological · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions: APX005M, Cabiralizumab, Nivolumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: sequential cord blood transplantation; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Optical coherence tomography; Device
Lead sponsor: Diagnostic Photonics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Annapolis, Maryland • Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, Nirogacestat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 1 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride, thalidomide, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer

Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)

Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Biodistribution and Dosimetry Evaluation of [124I]FIAU

Dose Escalation Study for Primary Hepatocellular Carcinoma

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Phase I Study of Sequential Cord Blood Transplants

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors